Importantly, this effect was specific to MLL-r cells, exhibiting minimal impact on MLL wild-type AML cell and normal hematopoiesis, and highlighting the potential of EP300/CREBBP as selective therapeutic targets for this aggressive leukemia subtype of MLL-r. Here, KMT2A is linked to acute myeloid leukemia.